Objectives: Endometriosis presents with significant pain as the most common symptom. Generic health measures can allow comparisons across diseases or populations. However, the Medical Outcomes Study Short Form 36 (SF-36) has not been validated for this disease. The goal of this study was to validate the SF-36 (version 2) for endometriosis.
Methods: Using data from two clinical trials (N = 252 and 198) of treatment for endometriosis, a full complement of psychometric analyses was performed. Additional instruments included a pain visual analog scale (VAS); a physician-completed questionnaire based on patient interview (modified Biberoglu and Behrman--B&B); clinical global impression of change (CGI-C); and patient satisfaction with treatment.
Results: Bodily pain (BP) and the Physical Component Summary Score (PCS) were correlated with the pain VAS at baseline and over time and the B&B at baseline and end of study. In addition, those who had the greatest change in BP and PCS also reported the greatest change on CGI-C and patient satisfaction with treatment. Other subscales showed smaller, but significant, correlations with change in the pain VAS, CGI-C, and patient satisfaction with treatment.
Conclusions: The SF-36--particularly BP and the PCS--appears to be a valid and responsive measure for endometriosis and its treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929048 | PMC |
| http://dx.doi.org/10.1007/s11136-013-0442-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Calcifying Tendinopathy of the Rotator Cuff: Barbotage vs. Shock Waves: Controlled Clinical Trial Protocol (BOTCH).
Healthcare (Basel)
December 2024
Interlevel Clinical Management Unit of Physical Medicine and Rehabilitation, Reina Sofía University Hospital, Córdoba and Guadalquivir Health District, 14011 Córdoba, Spain.
: Shoulder pain is a very common health issue among adults, being 8% due to calcifying tendinopathies (CT) of the shoulder. The evolutionary process of this lesion can be classified according to Bianchi Martinoli, depending on the ultrasound appearance. In 50% of cases, with first-line treatments, they resolve spontaneously.
View Article and Find Full Text PDFTherapeutic Approach to Primary Tic Disorders and Associated Psychiatric Comorbidities.
Brain Sci
December 2024
Movement Disorder Unit, Neurology Department, Hospital de Sant Pau, 08041 Barcelona, Spain.
Background/objectives: The treatment of tics and psychiatric comorbidities is crucial when they affect the patient's well-being and relationships. However, the optimal pharmacological treatment (PT) tailored to each patient's phenotype remains unclear. The primary objective of this study is to describe the clinical characteristics and treatment received for tics and psychiatric comorbidities in our cohort of children and adult patients with tic disorders.
View Article and Find Full Text PDFTherapeutic Effect of Evenamide, a Glutamate Inhibitor, in Patients With Treatment-Resistant Schizophrenia (TRS): Final, 1-Year Results From a Phase 2, Open-Label, Rater-Blinded, Randomized, International Clinical Trial.
Int J Neuropsychopharmacol
December 2024
NeurWrite LLC, Morristown, NJ, USA.
The results from a pilot, 1-year, randomized, open-label, add-on treatment study in treatment-resistant schizophrenia (TRS) with evenamide, a glutamate modulator, were not associated with any safety abnormalities at all doses (7.5-30 mg bid), with a high retention rate even at 6-month (~85%), and 1-year (~75%), and the absence of psychotic relapses during the 1-year treatment period. Overall, treatment with evenamide showed a gradual, sustained, and clinically important improvement up to 1 year in all efficacy measures (eg, PANSS mean change ~ -20%; CGI-S mean change ~ -1.
View Article and Find Full Text PDFPitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by CPAP: Randomised phase 3 study.
J Sleep Res
October 2024
HP2 Laboratory INSERM U1300, University Grenoble Alpes, Grenoble, France.
Article Synopsis
- Obstructive sleep apnea (OSA) often causes excessive daytime sleepiness (EDS), and pitolisant, a medication that targets histamine receptors, was tested for its efficacy in treating this issue in patients with moderate to severe OSA.
- In a clinical trial with 361 participants, pitolisant was administered in varying doses up to 40 mg daily for 12 weeks, showing a significant reduction in EDS as measured by the Epworth Sleepiness Scale compared to a placebo.
- The study found that pitolisant was well tolerated and improved not only daytime sleepiness but also reaction times and overall patient satisfaction, regardless of whether patients used continuous positive airway pressure (CPAP) therapy.
The effect of the EXOPULSE Mollii Suit on pain and fibromyalgia-related symptoms-A randomized sham-controlled crossover trial.
Eur J Pain
February 2025
Institut de la Colonne Vertébrale et Des Neurosciences (ICVNS), Centre Médico Chirurgical Bizet, Paris, France.
Article Synopsis
- A trial was conducted to assess the effects of the EXOPULSE Mollii Suit, a device that provides electrical nerve stimulation, on fibromyalgia symptoms including pain, fatigue, and quality of life.
- The study involved 33 adult patients with fibromyalgia in a double-blind, sham-controlled trial, demonstrating significantly reduced pain and improved symptoms after using the active device compared to the sham treatment.
- Results showed that after a 4-week active treatment period, most patients reported improvements in various outcomes, highlighting the potential clinical benefits of the EXOPULSE Mollii Suit for managing fibromyalgia symptoms.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!